Emerging agents to combat complicated and resistant infections: focus on ceftobiprole

References

• BushKHeepMMacielagMJNoelGJAnti-MRSA beta-lactams in development, with a focus on ceftobiprole: the first anti-MRSA beta-lactam to demonstrate clinical efficacyExpert Opin Investig Drugs2007164419429
   PubMed Web of Science ®Google Scholar
• NoelGJBushKBagchiPIanusJStraussRSA randomized, double-blind trial comparing ceftobiprole medocaril with vancomycin plus ceftazidime for the treatment of patients with complicated skin and skin-structure infectionsClin Infect Dis200846564765518225981
   PubMed Web of Science ®Google Scholar
• NoelGJStraussRSAmslerKHeepMPypstraRSolomkinJSResults of a double-blind, randomized trial of ceftobiprole treatment of complicated skin and skin structure infections caused by gram-positive bacteriaAntimicrob Agents Chemother2008521374417954698
   PubMed Web of Science ®Google Scholar
• El SolhACeftobiprole: a new broad spectrum cephalosporinExpert Opin Pharmacother200910101675168619527192
   PubMed Web of Science ®Google Scholar
• DeshpandeLRhombergPRFritscheTRSaderHSJonesRNBactericidal activity of BAL9141, a novel parenteral cephalosporin against contemporary Gram-positive and Gram-negative isolatesDiagn Microbiol Infect Dis2004501737515380281
   PubMed Web of Science ®Google Scholar
• DaviesTAPageMGShangWAndrewTKaniaMBushKBinding of ceftobiprole and comparators to the penicillin-binding proteins of Escherichia coli, Pseudomonas aeruginosa, Staphylococcus aureus, and Streptococcus pneumoniaeAntimicrob Agents Chemother20075172621262417470659
   PubMed Web of Science ®Google Scholar
• MoutonJWSchmitt-HoffmannAShapiroSNashedNPuntNCUse of Monte Carlo simulations to select therapeutic doses and provisional breakpoints of BAL9141Antimicrob Agents Chemother20044851713171815105125
   PubMed Web of Science ®Google Scholar
• Clinical and Laboratory Standards InstitutePerformance standards for antimicrobial susceptibility testing 17th informational supplement. CLSI document M100-S17 [ISBN 1-56238-625-5]Clinical and Laboratory Standards InstituteWayne, PA, USA2007
   Google Scholar
• AndereggTRJonesRNSaderHSQuality control guidelines for BAL9141 (Ro 63–9141), an investigational cephalosporin, when reference MIC and standardized disk diffusion susceptibility test methods are usedJ Clin Microbiol20044273356335815243116
   PubMed Web of Science ®Google Scholar
• BogdanovichTClarkCEdnieLActivities of ceftobiprole, a novel broad-spectrum cephalosporin, against Haemophilus influenzae and Moraxella catarrhalisAntimicrob Agents Chemother620065062050205716723565
   PubMed Web of Science ®Google Scholar
• BogdanovichTEdnieLMShapiroSAppelbaumPCAntistaphylococcal activity of ceftobiprole, a new broad-spectrum cephalosporinAntimicrob Agents Chemother200549104210421916189100
   PubMed Web of Science ®Google Scholar
• GoldsteinEJCitronDMMerriamCVWarrenYATyrrellKLFernandezHTIn vitro activity of ceftobiprole against aerobic and anaerobic strains isolated from diabetic foot infectionsAntimicrob Agents Chemother200650113959396216982780
   PubMed Web of Science ®Google Scholar
• IssaNCRouseMSPiperKEWilsonWRSteckelbergJMPatelRIn vitro activity of BAL9141 against clinical isolates of gram-negative bacteriaDiagn Microbiol Infect Dis2004481737514761726
   PubMed Web of Science ®Google Scholar
• ZbindenRPunterVvon GraevenitzAIn vitro activities of BAL9141, a novel broad-spectrum pyrrolidinone cephalosporin, against gram-negative nonfermentersAntimicrob Agents Chemother200246387187411850276
   PubMed Web of Science ®Google Scholar
• HebeisenPHeinze-KraussIAngehrnPHohlPPageMGThenRLIn vitro and in vivo properties of Ro 63–9141, a novel broad-spectrum cephalosporin with activity against methicillin-resistant staphylococciAntimicrob Agents Chemother200145382583611181368
   PubMed Web of Science ®Google Scholar
• JonesMEIn-vitro profile of a new beta-lactam, ceftobiprole, with activity against methicillin-resistant Staphylococcus aureusClin Microbiol Infect200713Suppl 2172417488372
   PubMed Web of Science ®Google Scholar
• von EiffCFriedrichAWBeckerKPetersGComparative in vitro activity of ceftobiprole against staphylococci displaying normal and small-colony variant phenotypesAntimicrob Agents Chemother200549104372437416189125
   PubMed Web of Science ®Google Scholar
• PillarCMAranzaMKShahDSahmDFIn vitro activity profile of ceftobiprole, an anti-MRSA cephalosporin, against recent gram-positive and gram-negative isolates of European originJ Antimicrob Chemother200861359560218218646
   PubMed Web of Science ®Google Scholar
• SrinivasanVMcGowanJEJrMcAllisterSTenoverFCIn vitro activity of ceftobiprole against coagulase-negative staphylococci isolated in the USAInt J Antimicrob Agents200831329429618180145
   PubMed Web of Science ®Google Scholar
• JonesRNDeshpandeLMMutnickAHBiedenbachDJIn vitro evaluation of BAL9141, a novel parenteral cephalosporin active against oxacillin-resistant staphylococciJ Antimicrob Chemother200250691593212461013
   PubMed Web of Science ®Google Scholar
• FritscheTRSaderHSJonesRNAntimicrobial activity of ceftobiprole, a novel anti-methicillin-resistant Staphylococcus aureus cephalosporin, tested against contemporary pathogens: results from the SENTRY Antimicrobial Surveillance Program (2005–2006)Diagn Microbiol Infect Dis2008611869518385000
   PubMed Web of Science ®Google Scholar
• RouseMSSteckelbergJMPatelRIn vitro activity of ceftobiprole, daptomycin, linezolid, and vancomycin against methicillin-resistant staphylococci associated with endocarditis and bone and joint infectionDiagn Microbiol Infect Dis200758336336517449212
   PubMed Web of Science ®Google Scholar
• ChungMAntignacAKimCTomaszAComparative study of the susceptibilities of major epidemic clones of methicillin-resistant Staphylococcus aureus to oxacillin and to the new broad-spectrum cephalosporin ceftobiproleAntimicrob Agents Chemother20085282709271718505853
   PubMed Web of Science ®Google Scholar
• LinGAppelbaumPCActivity of ceftobiprole compared with those of other agents against Staphylococcus aureus strains with different resistotypes by time-kill analysisDiagn Microbiol Infect Dis200860223323517997257
   PubMed Web of Science ®Google Scholar
• LeonardSNCheungCMRybakMJActivities of ceftobiprole, linezolid, vancomycin, and daptomycin against community-associated and hospital-associated methicillin-resistant Staphylococcus aureusAntimicrob Agents Chemother20085282974297618519721
   PubMed Web of Science ®Google Scholar
• YunHCEllisMWJorgensenJHActivity of ceftobiprole against community-associated methicillin-resistant Staphylococcus aureus isolates recently recovered from US military traineesDiagn Microbiol Infect Dis200759446346617911001
   PubMed Web of Science ®Google Scholar
• DeshpandeLMJonesRNBactericidal activity and synergy studies of BAL9141, a novel pyrrolidinone-3-ylidenemethyl cephem, tested against streptococci, enterococci and methicillin-resistant staphylococciClin Microbiol Infect20039111120112414616730
   PubMed Web of Science ®Google Scholar
• AriasCASinghKVPanessoDMurrayBETime-kill and synergism studies of ceftobiprole against Enterococcus faecalis, including beta-lactamase-producing and vancomycin-resistant isolatesAntimicrob Agents Chemother20075162043204717438057
   PubMed Web of Science ®Google Scholar
• KosowskaKHoellmanDBLinGAntipneumococcal activity of ceftobiprole, a novel broad-spectrum cephalosporinAntimicrob Agents Chemother20054951932194215855516
   PubMed Web of Science ®Google Scholar
• DaviesTAShangWBushKActivities of ceftobiprole and other beta-lactams against Streptococcus pneumoniae clinical isolates from the United States with defined substitutions in penicillin-binding proteins PBP 1a, PBP 2b, and PBP 2xAntimicrob Agents Chemother20065072530253216801437
   PubMed Web of Science ®Google Scholar
• HeckerSJChoISGlinkaTWDiscovery of MC-02,331, a new cephalosporin exhibiting potent activity against methicillin-resistant Staphylococcus aureusJ Antibiot (Tokyo)19985187227349766464
   PubMed Web of Science ®Google Scholar
• WalktyADecorbyMNicholKKarlowskyJAHobanDJZhanelGGIn vitro activity of ceftobiprole against clinical isolates of Pseudomonas aeruginosa obtained from Canadian intensive care unit (ICU) patients as part of the CAN-ICU StudyJ Antimicrob Chemother200862120620818385143
   PubMed Web of Science ®Google Scholar
• ThamlikitkulVTrakulsomboonSIn vitro activity of ceftobiprole against Burkholderia pseudomalleiJ Antimicrob Chemother200861246046118096556
   PubMed Web of Science ®Google Scholar
• EdnieLShapiroSAppelbaumPCAntianaerobe activity of ceftobiprole, a new broad-spectrum cephalosporinDiagn Microbiol Infect Dis200758113313617240107
   PubMed Web of Science ®Google Scholar
• WoottonMBowkerKEHoltHAMacGowanAPBAL 9141, a new broad-spectrum pyrrolidinone cephalosporin: activity against clinically significant anaerobes in comparison with 10 other antimicrobialsJ Antimicrob Chemother200249353553911864955
   PubMed Web of Science ®Google Scholar
• QueenanAMShangWKaniaMPageMGBushKInteractions of ceftobiprole with beta-lactamases from molecular classes A to DAntimicrob Agents Chemother20075193089309517591851
   PubMed Web of Science ®Google Scholar
• EntenzaJMHohlPHeinze-KraussIGlauserMPMoreillonPBAL9141, a novel extended-spectrum cephalosporin active against methicillin-resistant Staphylococcus aureus in treatment of experimental endocarditisAntimicrob Agents Chemother200246117117711751129
   PubMed Web of Science ®Google Scholar
• BanerjeeRGretesMBasuinoLStrynadkaNChambersHFIn vitro selection and characterization of ceftobiprole-resistant methicillin-resistant Staphylococcus aureusAntimicrob Agents Chemother20085262089209618378703
   PubMed Web of Science ®Google Scholar
• ChambersHFEvaluation of ceftobiprole in a rabbit model of aortic valve endocarditis due to methicillin-resistant and vancomycin-intermediate Staphylococcus aureusAntimicrob Agents Chemother200549388488815728879
   PubMed Web of Science ®Google Scholar
• VaudauxPGjinovciABentoMLiDSchrenzelJLewDPIntensive therapy with ceftobiprole medocaril of experimental foreign-body infection by methicillin-resistant Staphylococcus aureusAntimicrob Agents Chemother20054993789379316127054
   PubMed Web of Science ®Google Scholar
• YinLYCalhounJHThomasJKShapiroSSchmitt-HoffmannAEfficacies of ceftobiprole medocaril and comparators in a rabbit model of osteomyelitis due to methicillin-resistant Staphylococcus aureusAntimicrob Agents Chemother20085251618162218332175
   PubMed Web of Science ®Google Scholar
• AriasCASinghKVPanessoDMurrayBEEvaluation of ceftobiprole medocaril against Enterococcus faecalis in a mouse peritonitis modelJ Antimicrob Chemother200760359459817606481
   PubMed Web of Science ®Google Scholar
• RouseMSHeinMMAnguita-AlonsoPSteckelbergJMPatelRCeftobiprole medocaril (BAL5788) treatment of experimental Haemophilus influenzae, Enterobacter cloacae, and Klebsiella pneumoniae murine pneumoniaDiagn Microbiol Infect Dis200655433333616631339
   PubMed Web of Science ®Google Scholar
• Schmitt-HoffmannARoosBSchleimerMSingle-dose pharmacokinetics and safety of a novel broad-spectrum cephalosporin (BAL5788) in healthy volunteersAntimicrob Agents Chemother20044872570257515215110
   PubMed Web of Science ®Google Scholar
• Schmitt-HoffmannANymanLRoosBMultiple-dose pharmacokinetics and safety of a novel broad-spectrum cephalosporin (BAL5788) in healthy volunteersAntimicrob Agents Chemother20044872576258015215111
   PubMed Web of Science ®Google Scholar
• CraigWAAndesDRIn vivo pharmacodynamics of ceftobiprole against multiple bacterial pathogens in murine thigh and lung infection modelsAntimicrob Agents Chemother200852103492349618676887
   PubMed Web of Science ®Google Scholar
• LaohavaleesonSTessierPRNicolauDPPharmacodynamic characterization of ceftobiprole in experimental pneumonia caused by phenotypically diverse Staphylococcus aureus strainsAntimicrob Agents Chemother20085272389239418411322
   PubMed Web of Science ®Google Scholar
• LodiseTPJrPypstraRKahnJBProbability of target attainment for ceftobiprole as derived from a population pharmacokinetic analysis of 150 subjectsAntimicrob Agents Chemother20075172378238717387149
   PubMed Web of Science ®Google Scholar
• LodiseTPPatelNRenaud-MutartAGorodeckyEFritscheTRJonesRNPharmacokinetic and pharmacodynamic profile of ceftobiproleDiagn Microbiol Infect Dis20086119610218384996
   PubMed Web of Science ®Google Scholar
• Azoulay-DupuisEBedosJPMohlerJSchmitt-HoffmannASchleimerMShapiroSEfficacy of BAL5788, a prodrug of cephalosporin BAL9141, in a mouse model of acute pneumococcal pneumoniaAntimicrob Agents Chemother20044841105111115047508
   PubMed Web of Science ®Google Scholar
• PankuchGAAppelbaumPCPostantibiotic effect of ceftobiprole against 12 Gram-positive organismsAntimicrob Agents Chemother200650113956395817065631
   PubMed Web of Science ®Google Scholar